Acute myeloid leukemias with recurrent genetic abnormalities: Frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy [8]

Leukemia

Volumn 19, Issue 5, 2005, Pages 885-888

  Doubek, M ^a   Brychtova, Y ^a   Bercovcova, J ^a   Krejci, M ^a   Palasek, I ^a   Dvorakova, D ^a   Mayer, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG MEGADOSE; FEMALE; GENETIC DISORDER; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT CANCER;

EID: 18744363972     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403708     Document Type: Letter

References (7)

1. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
2. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002; 16: 1176-1181.
3. Krauter J, Görlich K, Ottmann O, Lübbert M, Döhner H, Heit W et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003; 21: 4413-4422.
4. Marucci G, Caligiuri MA, Döhner H, Archer KJ, Schlenk RF, Döhner K et al. Quantification of CBFβ/MYH11 fusion transcript by real time RT-PCR in patients with inv(16) acute myeloid leukemia. Leukemia 2002; 15: 1072-1080.
5. Viehmann S, Teigler-Schlegel A, Bruch J, Langebrake C, Reinhardt D, Harbott J. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003; 17: 1130-1136.
6. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746-2755.
7. Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21: 4496-4504.